Expanding our portfolio and delivering value

We evaluate opportunities regularly to enhance and expand our pharmaceutical and therapeutic portfolio. This includes new treatments in late-stage development and commercialized treatments.We maintain a global vision when sourcing, and our key markets for distribution are the US and Canada. Our focus is on therapies that address unmet needs in the treatment of psychiatric disorders and cardiovascular disease, as well as other disease states where we believe we can differentiate our offering.

If you would like to learn more and present HLS Therapeutics with commercialization or acquisition opportunities, please contact:

Pauline Dapena-Cherry
Director Corporate & Business Development
Email: p.dapenacherry@hlstherapeutics.com
Phone: 484-232-3400 ext. 107

Photo of Pauline Dapena-Cherry